AstraZeneca sells Seroquel rights in US and Canada
3rd Dec 2019 07:29
(Sharecast News) - AstraZeneca has agreed to sell the commercial rights to 'Seroquel' - quetiapine fumarate immediate release - and 'Seroquel XR' - quetiapine fumarate extended release - in the United States and Canada to Cheplapharm Arzneimittel, it announced on Tuesday.
Read moreAstraZeneca Imfinzi treatment gets FDA priority review
29th Nov 2019 07:05
(Sharecast News) - AstraZeneca said the US Food and Drug Administration had accepted a supplemental Biologics License Application (sBLA) and granted priority review for its Imfinzi treatment of patients with previously untreated extensive-stage small cell lung cancer.
Read moreFriday broker round-up
15th Nov 2019 13:09
(Sharecast News) - Whitbread: Barclays upgrades to overweight with a target price of 4,900p.
Read moreShoreCap stays at 'buy' on AstraZeneca after EU approves Qtrilmet
15th Nov 2019 11:25
(Sharecast News) - Analysts at ShoreCap reiterated their 'buy' recommendation on shares of AstraZeneca following news that Brussels had approved its Qtrilmet treatment for controlling blood sugar levels in patients suffering from Type-2 diabetes.
Read moreAstraZeneca gets EC approval for type-2 diabetes treatment
15th Nov 2019 07:28
(Sharecast News) - AstraZeneca announced on Friday that the European Commission has approved 'Qtrilmet' - metformin hydrochloride, saxagliptin and dapagliflozin - modified-release tablets to improve glycaemic control in adults with type-2 diabetes.
Read moreFDA accepts new drug application for AstraZeneca's selumetinib
14th Nov 2019 07:37
(Sharecast News) - AstraZeneca, along with its partner MSD, announced on Thursday that the US Food and Drug Administration (FDA) has accepted a new drug application (NDA) and granted 'Priority Review' status for selumetinib, as a potential new medicine for paediatric patients aged three years and older with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas.
Read moreTuesday broker round-up
12th Nov 2019 13:31
(Sharecast News) - BBA Aviation: HSBC downgrades to hold with a target price of 330p.
Read moreAstraZeneca's anifrolumab succeeds in lupus study
12th Nov 2019 08:05
(Sharecast News) - Biopharmaceutical giant AstraZeneca's anifrolumab demonstrated superiority across multiple efficacy endpoints versus placebos in the drug's Phase III TULIP 2 trial.
Read moreAstraZeneca upbeat on latest roxadustat trial data
11th Nov 2019 07:55
(Sharecast News) - AstraZeneca, along with its partner FibroGen, presented pooled efficacy and cardiovascular safety analyses from the pivotal phase 3 programme assessing 'roxadustat' on Monday, for the treatment of patients with anaemia from chronic kidney disease (CKD).
Read moreAstraZeneca reports positive trials for kidney drug
8th Nov 2019 07:50
(Sharecast News) - AstraZeneca on Friday reported clinical trials of its roxadustat drug for patients with anaemia from chronic kidney disease had significantly increased red haemoglobin levels.
Read moreThursday broker round-up
7th Nov 2019 13:28
(Sharecast News) - Associated British Foods: Goldman Sachs upgrades to buy with a target price of 2,750p.
Read moreAstraZeneca offloads Europe and Russia rights to 'Seroquel' medicines
30th Oct 2019 07:31
(Sharecast News) - AstraZeneca has agreed the sale and licence of the commercial rights to 'Seroquel' - quetiapine fumarate immediate release - and 'Seroquel XR' - quetiapine fumarate extended release - in Europe and Russia to Cheplapharm Arzneimittel, it announced on Wednesday.
Read moreLiberum upgrades AstraZeneca to 'buy' despite near-term premium
25th Oct 2019 13:23
(Sharecast News) - Analysts at Liberum upgraded their recommendation for shares of AstraZeneca, arguing that the consensus was - yet again - underestimating just how leveraged the firm was to its product pipeline.
Read moreFriday broker round-up
25th Oct 2019 12:56
(Sharecast News) - AstraZeneca: Liberum upgrades to buy with a target price of 8,250p.
Read moreAstraZeneca upgrades sales guidance after third quarter growth
24th Oct 2019 07:51
(Sharecast News) - AstraZeneca reported its year-to-date results following the end of its third quarter on Thursday, claiming that patients would benefit from further progress to its pipeline, while sales-growth momentum continued to drive its operating leverage.
Read more